Melinta Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: New Haven CT United States (2000)

Organization Overview

First Clinical Trial
2007
NCT00640926
First Marketed Drug
2014
oritavancin (orbactiv)
First NDA Approval
2014
oritavancin (orbactiv)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CMO, MelintaTherapeutics, Inc. | CMO, MelintaTtherapeutics, Inc. | MELINTA | MELINTA THERAP | Melinta Therapeutics, Inc. | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)